Table 1. Baseline characteristics (N = 48).
| Baseline characteristics | Median (IQR) or n (%) |
| Age, years | 52.5 (42.5–58.5) |
| % Female | 27 (56.3) |
| Race | |
| Caucasian | 27 (56.3) |
| African American | 19 (39.6) |
| Other | 2 (4.2) |
| ICU status/critically ill | |
| ICU | 16 (33.3) |
| Non-ICU | 32 (66.7) |
| Total body weight, kg | 122.5 (108.7–140.2) |
| Percent above ideal body weight | 206.5 (162–228.5) |
| SCr, mg/dL | 0.86 (0.63–0.99) |
| CrCl, mL/min | 122 (93–152.5) |
| Indication for therapy | |
| Pneumonia | 18 (37.5) |
| Cellulitis | 9 (18.8) |
| Empiric | 5 (10.4) |
| Febrile neutropenia | 3 (6.3) |
| Intra-abdominal infection | 3 (6.3) |
| Sepsis | 3 (6.3) |
| Meningitis | 2 (4.2) |
| Osteomyelitis | 1 (2.1) |
| UTI | 1 (2.1) |
| Other | 3 (6.3) |
| Goal trough | |
| 10–15 mcg/mL | 11 (22.9) |
| 15–20 mcg/mL | 37 (77.1) |
| Comorbidities | |
| Diabetes | 21 (43.8) |
| Malignancy | 12 (25) |
| Congestive heart failure | 8 (16.7) |
| Other | 7 (14.6) |
| End-stage liver disease | 1 (2.1) |
| Chronic kidney disease | 1 (2.1) |
| Hypermetabolic state | 1 (2.1) |
| No comorbidities | 14 (29.2) |
| Concomitant nephrotoxins | |
| Antimicrobials | 46 (95.8) |
| Piperacillin-tazobactam | 27 (56.3) |
| Other beta-lactams | 20 (41.7) |
| Fluoroquinolones | 11 (22.9) |
| Aminoglycosides | 3 (6.3) |
| Other antimicrobials | 12 (25.0) |
| Other nephrotoxins | 32 (66.7) |
| Diuretics | 23 (47.9) |
| Contrast medication | 17 (35.4) |
| NSAIDs | 4 (8.3) |
| Length of stay, days | 10.5 (7–19.5) |
| ICU length of stay, days | 7.5 (3.5–15) |
| Duration of therapy, days | 4 (3–6) |
Note: CrCl = creatinine clearance; ICU = intensive care unit; NSAIDs = nonsteroidal anti-inflammatory drugs; SCr = serum creatinine; UTI = urinary tract infection.